:’
Arcutis Biotherapeutics, Inc. has completed enrollment for its Phase 2 clinical trial, INTEGUMENT-INFANT, assessing the safety and efficacy of ZORYVE (roflumilast) cream 0.05% in infants diagnosed with atopic dermatitis (AD). This study is part of Arcutis’ broader clinical development program for roflumilast, which has shown promise in other dermatological applications, including psoriasis.
Atopic dermatitis is a chronic inflammatory skin condition that commonly affects infants and young children. Current treatment options often have limitations in safety and efficacy, creating a demand for new therapies. ZORYVE, a topical phosphodiesterase-4 (PDE4) inhibitor, has been previously studied in adults and adolescents with psoriasis, showing favorable results for effectiveness and tolerability. The advancement of clinical studies into younger populations, particularly infants, is critical for providing safe and effective treatments for this vulnerable demographic.
Phase 2 INTEGUMENT-INFANT Study:’
The INTEGUMENT-INFANT study aims to evaluate the safety, tolerability, and potential efficacy of ZORYVE cream in infants with atopic dermatitis. Enrollment has now been completed, marking a significant milestone in the drug development process. This open-label clinical trial will assess infants aged six months to two years diagnosed with mild to moderate AD.
The primary endpoints include the safety profile of the cream and its tolerability in this age group over the treatment period. Secondary endpoints will focus on clinical efficacy, utilizing common assessment scales for atopic dermatitis, such as the Investigator’s Global Assessment (IGA) and the Eczema Area and Severity Index (EASI).
Previous Studies and Context:’
Prior to the INTEGUMENT-INFANT trial, Arcutis published results from the ARRECTOR trial in JAMA Dermatology, showcasing the efficacy and safety of ZORYVE foam 0.3% in older children and adults with psoriasis. The positive outcomes from this Phase 3 trial set a precedent for the potential effectiveness of roflumilast in managing inflammatory skin conditions.
Conclusion:’
As Arcutis completes enrollment in the INTEGUMENT-INFANT study, the dermatology community awaits data that could expand the therapeutic options available for infants with atopic dermatitis. The transition of investigations into pediatrics underscores the ongoing need to address inflammatory skin disorders in younger patient populations. Continued monitoring and publication of findings will be crucial for determining the appropriateness of roflumilast in this vulnerable age group, contributing to the evolving landscape of dermatologic therapeutics.
Future results from the INTEGUMENT-INFANT trial may indicate whether roflumilast can provide a novel therapeutic approach for infants battling atopic dermatitis, aligning with Arcutis’ commitment to bringing innovative treatments to patients with unmet medical needs.
Comments